Aspects of xerostomia prevalence and treatment among rheumatic inpatients

Medicina

Volumn 44, Issue 12, 2008, Pages 960-968

  Guobis, Žygimantas ^a   Basevičiene, Nomeda ^a   Paipaliene, Pajauta ^a   Niedzelskiene, Irena ^a   Januševičiute, Giedre E ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Caries; Rheumatic diseases; Treatment; Xerophthalmia; Xerostomia

Indexed keywords

ADULT; AGE; ARTICLE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; EVALUATION; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGE FACTORS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DATA COLLECTION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SEX FACTORS; SJOGREN'S SYNDROME; XEROPHTHALMIA; XEROSTOMIA;

EID: 59149096495     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina44120120     Document Type: Article

References (48)

1. Atkinson JC, Wu AJ. Salivary gland dysfunction: causes, symptoms, treatment. J Am Dent Assoc 1994;125(4):409-16.
2. Aguirre A. Recognizing and managing the oral clues that point to Sjögren's syndrome. Medscape Womens Health 1997;2(9):2.
3. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 2003;134(1):61-9.
4. Patinen P, Aine L, Collin P, Hietanen J, Korpela M, Enckell G, et al. Oral findings in coeliac disease and Sjögren's syndrome. Oral Dis 2004;10(6):330-4.
5. Humprey SP, Williamson RT. A review of saliva: normal composition, flow and function. J Prosthet Dent 2001;85: 162-9.
6. Tenovuo J. Invited review: antimicrobial function of human saliva - how important is it for oral health. Acta Odontol Scand 1998;56(5):250-6.
7. Ishijima T, Koshino H, Hirai T, Takasaki H. The relationship between salivary secretion rate and masticatory efficiency. J Oral Rehabil 2004;31:3-6.
8. Triantos D, Kanakis P. Stomatodynia (burning mouth) as a complication of enalapril therapy. Oral Dis 2004;10(4):244-5.
9. Bergdahl J, Bergdahl M. Environmental illness: evaluation of salivary flow, symptoms, diseases, medications and psychological factors. Acta Odontol Scand 2001;59(2):104-10.
10. Anttila SS, Knuuttila ML, Sakki TK. Depressive symptoms as an underlying factor of the sensation of dry mouth. Psychosom Med 1998;60(2):215-8.
11. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis 2003;9(4):165-76.
12. Ranyonen P. Salivary flow and composition in healthy and diseased adults [dissertation]. Helsinki: 2003.
13. Mandel SJ, Mandel L. False-positive xerostomia following radioactive iodine treatment: case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(2):e43-7.
14. Nederfors T. Xerostomia and hyposalivation. Adv Dent Res 2000;14:48-56.
15. Nederfors T, Isaksson R, Mornstad H, Dahlof C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population - relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 1997;25:211-6.
16. Gilbert GH, Heft MW, Duncan RP. Mouth dryness as reported by older Floridians. Community Dent Oral Epidemiol 1993;21:390-7.
17. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:641-9.
18. Parvinen T, Larmas M. The relation of stimulated salivary flow rate and pH to Lactobacillus and yeast concentrations in saliva. J Dent Res 1981;60(12):1929-35.
19. Navazesh M, Wood GJ, Brightman VJ. Relationship between salivary flow rates and Candida albicans counts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:284-8.
20. Smith G, Smith AJ, Shaw L, Shaw MJ. Artificial saliva substitutes and mineral dissolution. J Oral Rehabil 2001; 28(8):728-31.
21. Najera MP, al-Hashimi I, Plemons JM, Rivera-Hidalgo F, Rees TD, Haghighat N, et al. Prevalence of periodontal disease in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83(4):453-7.
22. Spak CJ, Johnson G, Ekstrand J. Caries incidence, salivary flow rate and efficacy of fluoride gel treatment in irradiated patients. Caries Res 1994;28(5):388-93.
23. Keene JJ Jr, Galasko GT, Land MF. Antidepressant use in psychiatry and medicine: importance for dental practice. J Am Dent Assoc 2003;134(1):71-9.
24. Boyd LD, Dwyer JT, Papas A. Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. Nutr Rev 1997;55(10):362-8.
25. Pillemer SR, Matteson EL, Jacobsson LTH, Martens PB, Melton LJ, O'Fallon WM, et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001;76:593-59. Available from: URL: http://www.mayoclinicproceedings.com/inside.asp?AID=1208&UID=
26. Meyerowitz C, Featherstone JD, Billings RJ, Eisenberg AD, Fu J, Shariati M, et al. Use of an intra-oral model to evaluate 0.05% sodium fluoride mouthrinse in radiation-induced hyposalivation. J Dent Res 1991;70(5):894-8.
27. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993; 329(6):390-5.
28. Peeters FP, deVries MW, Vissink A. Risks for oral health with the use of antidepressants. Gen Hosp Psychiatry 1998; 20(3):150-4.
29. Silvestre FJ, Plaza A, Serrano C. Prevention and management of radiotherapy complications in patients with head and neck tumors. Med Oral 1998;3:136-47.
30. Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09. Int J Radiat Oncol Biol Phys 2003;56(3):832-6.
31. Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L. Mechanisms for radiation-induced oral mucositis and the consequences. Cancer Nurs 2003;26(3):222-9.
32. Leone CW, Oppenheim FG. Physical and chemical aspects of saliva as indicators of risk for dental caries in humans. Available from: URL: http://www.nidr.nih.gov/news/CONSENSUS/Cataldo_Leone.pdf
33. Kaufman I, Schwartz D, Caspi D, Paran D. Sjögren's syndrome - not just sicca: renal involvement in Sjögren's syndrome. Scand J Rheumatol. 2008 May-Jun;37(3):213-8.
34. Wall GC, Magarity ML, Jundt JW. Pharmacotherapy of xerostomia in primary Sjogren's syndrome. Pharmacotherapy 2002;22(5):621-9.
35. Jorkjend L, Johansson A, Johansson AK, Bergenholtz A. Periodontitis, caries and salivary factors in Sjögren's syndrome patients compared to sex- and age-matched controls. J Oral Rehabil 2003;30(4):369-78.
36. Koseki M, Maki Y, Matsukubo T, Ohashi Y, Tsubota K. Salivary flow and its relationship to oral signs and symptoms in patients with dry eyes. Oral Dis 2004;10(2):75-80.
37. Baker SR, Pankhurst CL, Robinson PG. Testing relationships between clinical and non-clinical variables in xerostomia: A structural equation models of oral health-related quality of life. Quality of life research (2006), DOI 10.1007/s11136-006-9108-x. Springer; 2006.
38. Baker SR, Pankhurst CL, Robinson PG. Utility of two oral health-related quality-of-life measures in patients with xerostomia. Community Dent Oral Epidemiol 2006;34:351-62.
39. Pace-Balzan A, Cawood JI, Howell R, Lowe D, Rogers SN. The Liverpool oral rehabilitation questionnaire: a pilot study. J Oral Rehabilitation 2004;31;609-17.
40. Braam PM, Roesink JM, Raaijmakers CPJ, Busschers WB, Terhaard ChHJ. Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiation Oncology 2007;2:3.
41. Field EA, Rostron JL, Longman LP, Bowman SJ, Lowe D, Rogers SN. The development and initial validation of the Liverpool sicca index to asses symptoms and dysfunction in patients with primary Sjögren's syndrome. J Oral Pathol Med 2003;32:154-62.
42. Hamburger J. Sjögren's syndrome - managing oral and systemic symptoms via a multi-disciplinary approach. Oral Dis 2004;10:306-9.
43. Pedersen AML, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol 2005,5:4.
44. Morbini P, Manzo A, Caporali R, Epis O, Villa Ch, Tinelli C, et al. Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Res Ther 2005;7:R343-8.
45. Heft MW, Baum BJ. Unstimulated and stimulated parotid salivary flow rate in individuals of different ages. J Dent Res 1984;63(10):1182-5.
46. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 2000;79(9):1652-8.
47. Grieve M. Bearberry. Botanical.com. Available from: URL: http://www.botanical.com/botanical/mgmh/b/bearbe22.html
48. Rosas J, Ramos-Casals M, Ena J, Garcia-Carrasco M, Verdu J, Cervera R, et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren's syndrome. Correlation with clinical, immunological and histological features. Rheumatology 2002;41:670-5.